Cardioselective Beta‐Blockers in Patients with Asthma and Concomitant Heart Failure or History of Myocardial Infarction: When Do Benefits Outweigh Risks?

References

• Packer M, Bristow M R, Cohn J N, Colucci W S, Fowler M B, Gilbert E M, Shusterman N H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355
   PubMed Web of Science ®Google Scholar
• The Australia‐New Zealand Heart Failure Reseach Collaborative Group. Randomised, placebo‐controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–380
   PubMedGoogle Scholar
• Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J P. Clinical effects of beta adrenergic blockade in chronic heart failure: a meta‐analysis of double‐blind, placebo‐controlled, randomized trials. Circulation 1998; 98: 1184–1191
   PubMed Web of Science ®Google Scholar
• CIBIS‐II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS‐II): a randomised trial. Lancet 1999; 353: 9–13
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus K L, Janosi A, Thorgeirsson G, Dunselman P H, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled‐release metoprolol on total mortality, hospitalizations and well‐being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT‐HF). JAMA 2000; 283: 1295–1302
   PubMed Web of Science ®Google Scholar
• Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Pharmacotherapy 2000; 20: 495–522
   PubMedGoogle Scholar
• Beta‐Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982; 247: 1707–1714
   PubMed Web of Science ®Google Scholar
• The Norwegian Multicenter Study Group. Timolol‐induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–807
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Emfeldt D, Herlitz A, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction: a double‐blind randomised trial. Lancet 1981; 2: 823–827
   PubMed Web of Science ®Google Scholar
• Committee on Management of Acute Myocardial Infarction. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1328–1428
   PubMedGoogle Scholar
• Ellerbeck E F, Jencks S F, Radford M J, Kresowik T F, Craig A S, Gold J A, Krumholz H M, Vogel R A. Quality of care for Medicare patients with acute myocardial infarction: a four‐state pilot study from the Cooperative Cardiovascular Project. JAMA 1995; 273: 1509–1514
   PubMed Web of Science ®Google Scholar
• Brand D A, Newcomer L N, Freiburger A, Tian H. Cardiologists' practices compared with practice guidelines: use of beta‐blockade after acute myocardial infarction. J Am Coll Cardiol 1995; 26: 1423–1426
   Google Scholar
• Viskin S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, Zajarias A, Laniado S, Belhassen B. Treatment with beta‐adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995; 25: 1327–1332
   PubMedGoogle Scholar
• Barron H V, Viskin S, Lundstrom R J. Beta‐blocker dosages and mortality after myocardial infarction. Arch Intern Med 1998; 158: 449–453
   PubMed Web of Science ®Google Scholar
• Gottlieb S S, McCarter R J, Vogel R A. Effect of beta‐blockade on mortality among high‐risk and low‐risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497
   PubMed Web of Science ®Google Scholar
• Krumholz H M, Radford M J, Wang Y, Chen J, Heiat A, Marciniak T A. National use and effectiveness of beta blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998; 280: 623–629
   PubMed Web of Science ®Google Scholar
• Komajda M, Follath F, Swedberg K, Cleland J, Aguilar J C, Cohen‐Solal A, Dietz R, Gavazzi A, Van Gilst W H, Hobbs R, Korewicki J, Madeira H C, Moiseyev V S, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–474
   PubMed Web of Science ®Google Scholar
• McNeill R S. Effect of a beta adrenergic blocking agent, propranolol, on asthmatics. Lancet 1964; 2: 1101–1102
   PubMed Web of Science ®Google Scholar
• McNeill R S, Ingram C G. Effect of propranolol on ventilatory function. Am J Cardiol 1966; 18: 473–475
   PubMed Web of Science ®Google Scholar
• Raine J M, Palazzo M G, Kerr J H, Sleight P. Near fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halthane. BMJ 1981; 282: 548–549
   PubMedGoogle Scholar
• Williams I P, Millard F JC. Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980; 35: 160
   PubMedGoogle Scholar
• Harries A D. Beta blockade in asthma. BMJ 1981; 282: 1321
   PubMedGoogle Scholar
• Fraunfelder F T, Barker A F. Respiratory effects of timolol. N Engl J Med 1984; 311: 1441
   PubMed Web of Science ®Google Scholar
• Odeh M, Oliven A, Bassan H. Timolol eyedrop‐induced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991; 32: 97–98
   PubMed Web of Science ®Google Scholar
• Wilcox P G, Ahmad D, Darke A C, Parsons J, Carruthers S G. Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther 1986; 39: 29–34
   PubMedGoogle Scholar
• Ellis M E, Sahah J N, Chatterjee S S, Cruickshank J M, Ellis S H. Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol 1981; 21: 173–176
   PubMedGoogle Scholar
• Clague H, Ahmad D, Carruthers S G. Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta blockade. Eur J Clin Pharmacol 1984; 27: 517–523
   PubMed Web of Science ®Google Scholar
• Salpeter S R, Ormiston T M, Salpeter E E. Cardioselective beta blockers in patients with reactive airway disease: a meta‐analysis. Ann Intern Med 2002; 137: 715–725
   PubMed Web of Science ®Google Scholar
• Epstein P E. Fresh air and beta blockade. Ann Intern Med 2002; 137: 766–767
   PubMedGoogle Scholar
• Chafin C C, Soberman J E, Demirkan K, Self T. Beta‐blockers after myocardial infarction: do benefits ever outweigh risks in asthma. Cardiology 1999; 92: 99–105
   PubMed Web of Science ®Google Scholar
• Nicolaescu V, Manivadite M, Stroescu V. Beta adrenergic blockade with practolol in acetylcholine‐sensitive asthma patients. Respiration 1972; 29: 139–154
   PubMed Web of Science ®Google Scholar
• Nicolaescu V, Racoveanu C, Manicatide M. Effects of exercise on practolol‐treated asthmatic patients. Eur J Clin Pharmacol 1973; 6: 3–8
   PubMedGoogle Scholar
• Johnsson G, Svedmyr N, Thiringer G. Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate, and blood pressure in asthmatics. Eur J Clin Pharmacol 1975; 8: 175–180
   PubMed Web of Science ®Google Scholar
• Skinner C, Palmer K N. Comparison of the effects of acebutolol and practolol on airways obstruction in asthmatics. Br J Clin Pharmacol 1978; 5: 415–419
   PubMedGoogle Scholar
• Benson M K, Berrill W T, Cruickshank J M, Sterling G S. A comparison of four beta adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5: 415–419
   PubMed Web of Science ®Google Scholar
• Ruffin R E, Frith P A, Anderton R C, Kumana C R, Newhouse M T, Hargreave F E. Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation. Clin Pharmacol Ther 1979; 25: 536–540
   PubMedGoogle Scholar
• Lofdahl C G, Svedmyr N. Cardioselectivity of atenolol and metoprolol: a study in asthmatic patients. Eur J Respir Dis 1981; 62: 396–404
   PubMedGoogle Scholar
• Van den Bergh J H, van Herwaarden C L. Ventilatory effects of ordinary and slow‐release tablets of metoprolol in asthmatic patients. Eur J Respir Dis 1981; 62: 168–172
   PubMedGoogle Scholar
• Lawrence D S, Sahay J N, Chatterjee S S, Cruickshank J M. Asthma and beta blockers. Eur J Clin Pharmacol 1982; 22: 501–509
   PubMedGoogle Scholar
• Greefhorst A P, van Herwaarden C L. Ventilatory and haemodynamic effects of beta 1‐selective and beta 2‐selective stimulation in asthmatic patients. Eur J Respir Dis, Suppl 1984; 135: 147–150
   PubMedGoogle Scholar
• Lammers J W, Folgering H T, van Herwaarden C L. Ventilatory effects of beta1‐receptor‐selective blockade with bisoprolol and metoprolol in asthmatic patients. Eur J Clin Pharmacol 1984; 27: 141–145
   PubMedGoogle Scholar
• Doshan H D, Rosenthal R R, Brown R, Slutsky A, Applin W J, Caruso F S. Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. J Cardiovasc Pharmacol 1986; 8(Suppl. 4)S105–S108
   PubMedGoogle Scholar
• Doshan H D, Brown R, Applin W J, Kapoor M, Caruso F S. Effects of high doses of celiprolol in asthmatic patients. J Cardiovasc Pharmacol 1986; 8(Suppl. 4)S109–S111
   PubMedGoogle Scholar
• Chatterjee S S. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol 1986; 8(Suppl. 11)S74–S77
   Google Scholar
• Lammers J W, Muller M E, Folgering H T, van Herwaarden C L. A comparative study on the ventilatory and haemodynamic effects xamoterol and atenolol in asthmatic patients. Br J Clin Pharmacol 1986; 22: 595–602
   PubMedGoogle Scholar
• Falliers C J, Vincent M E, Medakovic M. Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol. J Asthma 1986; 23: 251–260
   PubMed Web of Science ®Google Scholar
• Chodosh S, Tuck J, Blasucci D J. The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics. J Cardiovasc Pharmacol 1988; 11(Suppl. 2)S18–S24
   Google Scholar
• Lammers J W, Muller M E, Folgering H T, van Herwaarden C L. Effects of terbutaline and atenolol on large and small airways in asthmatic patients. Eur Respir J 1988; 1: 453–457
   PubMedGoogle Scholar
• Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive pulmonary disease. Cardiovasc Drugs Ther 1990; 4: 1145–1149
   PubMedGoogle Scholar
• Tantucci C, Bruni B, Dottorini M L, Peccini F, Motolese M, Lecaillon J B, Sorbini C A, Grassi V. Comparative evaluation of cardioselectivity of metoprolol OROS and atenolol: a double‐blind, placebo‐controlled crossover study. Am Heart J 1990; 120: 467–472
   PubMedGoogle Scholar
• Plosker G L, Clissold S P. Controlled release metoprolol formulations. Drugs 1992; 43: 382–414
   PubMedGoogle Scholar
• Decalmer P BS, Chatterjee S S, Cruickshank J M, Benson M K, Sterling G M. Beta blockers and asthma. Br Heart J 1978; 40: 184–189
   PubMedGoogle Scholar
• van Zyl A I, Jennings A A, Bateman E D, Oie L H. Comparison of respiratory effects of two cardioselective beta blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. Chest 1989; 95: 209–213
   PubMedGoogle Scholar
• Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 1976; 3: 1007–1014
   PubMed Web of Science ®Google Scholar
• Klein L, O'Connor C M, Gattis W A, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003; 91(Suppl. 9A)18F–40F
   Google Scholar
• MERIT‐HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT‐HF). Lancet 1999; 353: 9–13
   PubMedGoogle Scholar
• Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). J Am Coll Cardiol 2002; 7: 491–498
   Google Scholar
• Kotlyar E, Keogh A M, Macdonald P S, Arnold R H, McCaffrey D J, Glanvile A R. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21: 1290–1295
   PubMed Web of Science ®Google Scholar
• Frishman W H. Carvedilol. N Engl J Med 1998; 339: 1759–1765
   PubMed Web of Science ®Google Scholar
• Coreg (carvedilol) product literature. Physicians' Desk Reference57th ed. Thomson PDR, Montavale, NJ 2003; 1491–1496
   Google Scholar
• Sturm B, Pacher R, Strametz‐Juranek J, Berger R, Frey B, Stanek B. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high‐dose enalapril. Eur J Heart Fail 2000; 2: 407–412
   PubMedGoogle Scholar
• Hulsmann M, Sturm B, Pacher R, Berger R, Bojic A, Frey B, Stanek B. Long term effect of atenolol on ejection fraction, symptoms and exercise variables in patients with advanced left ventricular dysfunction. J Heart Lung Transplant 2001; 20: 1174–1180
   PubMedGoogle Scholar
• Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985; 5: 1428–1437
   PubMedGoogle Scholar
• Wilcox R G, Roland J M, Banks D C, Hampton J R, Mitchell J RA. Randomized trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J 1980; 280: 885–888
   PubMedGoogle Scholar
• Rochon P A, Tu J V, Anderson G M, Gurwitz J H, Clark J P, Lau P, Szalai J P, Sykora K, Naylor C D. Rate of heart failure and 1‐year survival for older people receiving low‐dose beta‐blocker therapy after myocardial infarction. Lancet 2000; 356: 639–644
   PubMedGoogle Scholar
• Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD 1997, NIH Publication No. 97‐4051
   Google Scholar
• Executive Summary of the NAEPP Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma—Update on Selected Topics 2002. National Institutes of Health, Bethesda, MD 2002, NIH Publication No. 02‐5075
   Google Scholar
• Tan S, Hall I P, Dewar J, Dow E, Lipworth B. Association between beta2 adrenoceptor polymorphism and susceptibility to bronchodilatory desensitization in moderately severe stable asthmatics. Lancet 1997; 350: 995–999
   PubMed Web of Science ®Google Scholar
• Krum H. Beta‐blockers in chronic heart failure: what have we learned? What do we still need to know?. Curr Opin Pharmacol 2003; 3: 168–174
   PubMedGoogle Scholar
• Cockcroft D W. Management of acute severe asthma. Ann Allergy, Asthma, & Immun 1995; 75: 83–89
   PubMed Web of Science ®Google Scholar
• Ind P W, Dixon C MS, Fuller R W, Barnes P J. Anticholinergic blockade of beta‐blocker‐induced bronchoconstriction. Am Rev Respir Dis 1989; 139: 1390–1394
   PubMedGoogle Scholar
• Giulekas D, Georgopoulos D, Papakosta D, Antoniadou H, Sotiropoulou E, Vamvalis C. Influence of pindolol on asthmatics and effect of bronchodilators. Respiration 1986; 50: 158–166
   PubMedGoogle Scholar
• Bradley D J, Bradley E A, Baughman K L, Berger R D, Calkins H, Goodman S N, Kass D A, Powe N R. Cardiac resynchronization and death from progressive heart failure, a meta‐analysis of randomized controlled trials. JAMA 2003; 289: 730–740
   PubMed Web of Science ®Google Scholar